Mefenorex

Mefenorex
Clinical data
Trade names	Rondimen, Pondinil, Anexate
ATC code	A08AA09 (WHO) ;
Legal status
Legal status	BR: Class B2 (Anorectic drugs); CA: Schedule I; DE: Anlage II (Authorized trade only, not prescriptible);
Identifiers
	IUPAC name 3-chloro-N-(1-methyl-2-phenylethyl)propan-1-amine;
CAS Number	17243-57-1 ;
PubChem CID	21777;
ChemSpider	20467 ;
UNII	K98M4N387W;
KEGG	D07891 ;
CompTox Dashboard (EPA)	DTXSID6057665 ;
ECHA InfoCard	100.037.511
Chemical and physical data
Formula	C12H18ClN
Molar mass	211.73 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES ClCCCNC(Cc1ccccc1)C;
	InChI InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3 ; Key:XXVROGAVTTXONC-UHFFFAOYSA-N ;
	(verify)

Mefenorex (marketed as Rondimen, Pondinil, Anexate) is an amphetamine derivative with a relatively mild psychostimulant profile. Developed in the 1960s, it was used throughout the 1970s as an appetite suppressant for treating obesity.^[2]^[3] Mefenorex is a prodrug of amphetamine; upon ingestion, the compound will begin to metabolize into, as well as promote the production of, the active metabolites levoamphetamine and dextroamphetamine.^[4] Multiple sources have noted the substance as exerting "mild stimulant effects....[and having] relatively little abuse potential."^[5]